TOPPER

Tag Archives | MEDITE Cancer Diagnostics, Inc.

News image: medical devices

NEWS: MEDITE Cancer Diagnostics, Inc. will present at the SeeThruEquity Healthcare Investor Conference on January 11

ORLANDO, Fla., Jan. 7, 2016 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (OTC:MDIT / OTCMKTS:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity […]

Continue Reading
News image: premium medical devices

NEWS: MEDITE Cancer Diagnostics, Inc. Reports a Profitable Third Quarter and Nine Month 2015 Results

ORLANDO, Fla., Nov. 17, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT, the ‘Company’ / OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its third quarter and nine month 2015 results.

Continue Reading
News image: tissue staining machines

NEWS: MEDITE Cancer Diagnostics, Inc. successfully obtained Mexican Tender for 31 Stainers and First Delivery of new Manual Microtome to China

ORLANDO, Fla., Aug. 27, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc., (OTC/QB: MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its Mexican distributor, ATYDE won a public tender for delivery of 31 MEDITE tissue staining […]

Continue Reading
News image: medical devices

NEWS: MEDITE Cancer Diagnostics, Inc. Reports Second Quarter and Six Month 2015 Results

ORLANDO, Fla., Aug. 17, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (‘Company,’ OTCQB symbol: MDIT / OTCBB:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces second quarter and six month 2015 results.

Continue Reading
News image: molecular biomarkers

NEWS: MEDITE Cancer Diagnostics, Inc. Announces Change of Auditor

ORLANDO, Fla., May 14, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (‘Company,’ OTCQB symbol: ‘MDIT’ / OTCBB:MDIT), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces change of auditors.

Continue Reading

Part of the Neotrope® News Network, USA.